Responsibilities
* Lead the statistical design and strategy to product development plans, preclinical studies, regulatory strategy, health technology assessment and/or commercial activities as appropriate for the stage of the product.
* Lead the statistical content and ensure quality for study designs, documents, delivery and interpretation and submission.
* Quantify the benefit, risk, value and uncertainty of the emerging product profile and can communicate these effectively within the team.
* Provide global leadership to others and direct project work delivered by internal and external staff.
* Partner with CROs to ensure delivery to quality and time.
* Represent AZ externally which may include health authorities, advisory boards, conferences, workshops and/or payer interactions.
Qualifications
* A Statistics, Mathematics, Biostatistics-related MS Degree.
* Strong, proven experience in statistical role in the pharmaceutical or healthcare industry.
* Direct experience of clinical trials in pharmaceuticals or healthcare environment.
* Excellent interpersonal skills.
* A collaborative mindset.
* Genuine dedication to drive innovation to advance statistical science.
* Prior oncology experience.
Preferred
* Ph.D. in Statistics or Mathematics with high statistical component.
* Project Management Skills.
* Proficiency in SAS and R/Python language.
* Track record of research and methodological development in Statistics, supported by scientific publications in first‑class statistical journals.
* Knowledge of Bayesian statistics from theory to computation is a plus.
AstraZeneca is a global, science‑led, patient‑focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world's most serious disease. But we're more than one of the world's leading pharmaceutical companies.
Join the team dedicated to Oncology, with an ambition to eliminate cancer as a cause of death. It's our big vision that unites and encourages us. With multiple indications and high‑quality molecules at all stages of our innovative pipeline, we keep pushing forward. Fusing cutting‑edge science with the latest technology to achieve breakthroughs. Backed by investment, we are striving to deliver 6 new molecular entities by 2025. We work on some of the most sophisticated and exciting challenges. A fast‑paced and agile team, we are empowered and trusted to innovate and experiment. With access to our extensive capabilities and comprehensive pipeline, you'll be involved in countless submissions and a wide range of engaging projects along the complete drug development process.
#J-18808-Ljbffr